Pliant Therapeutics' Lead Oncology Candidate PLN-101095 Shows Deepening Responses, Advances to Phase 1b
summarizeSummary
Pliant Therapeutics announced significant positive updates for its lead oncology candidate, PLN-101095, including the dosing of the first participant in the FORTIFY Phase 1b indication expansion trial ahead of schedule. Updated data from the Phase 1 trial, presented at AACR 2026, highlighted deepening of confirmed responses, including one complete response and two partial responses, in patients with checkpoint inhibitor-refractory solid tumors. The drug was also spotlighted at AACR's Highlights Plenary Session, underscoring its potential as a novel immunotherapy approach. This progress is highly material for the clinical-stage biotech, building on the company's previously stated focus on accelerating PLN-101095 development. While Q1 2026 financial results were mentioned, no specific figures were provided. Investors will be watching for interim data from the FORTIFY trial, expected in 2027.
At the time of this announcement, PLRX was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.3M. The 52-week trading range was $1.09 to $1.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.